Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model
about
Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trialAdeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 yearStructure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene TherapyCardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling.Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery.Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling.Plectin-1 Targeted AAV Vector for the Molecular Imaging of Pancreatic Cancer.Genetic fate of recombinant adeno-associated virus vector genomes in muscleStriatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.Gene therapy targeting glaucoma: where are we?Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Characterization of adeno-associated virus genomes isolated from human tissues.Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain.Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brainAdeno-associated viruses undergo substantial evolution in primates during natural infections.Current status of gene therapy for inherited lung diseasesRibozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy.A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculationExamining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.Prediction of adeno-associated virus neutralizing antibody activity for clinical application.Complement is an essential component of the immune response to adeno-associated virus vectors.Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection againstRenal rescue of dopamine D2 receptor function reverses renal injury and high blood pressureInfectious molecular clones of adeno-associated virus isolated directly from human tissues.Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.PTPIP51 regulates mouse cardiac ischemia/reperfusion through mediating the mitochondria-SR junction.Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway.Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery.Herpes simplex virus type 1 ICP0 protein mediates activation of adeno-associated virus type 2 rep gene expression from a latent integrated form.AAV-mediated delivery of optogenetic constructs to the macaque brain triggers humoral immune responses.High Prevalence of Infectious Adeno-associated Virus (AAV) in Human Peripheral Blood Mononuclear Cells Indicative of T Lymphocytes as Sites of AAV Persistence.Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral Vectors.Flexible, AAV-equipped Genetic Modules for Inducible Control of Gene Expression in Mammalian Brain.Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.Impact of the MRN Complex on Adeno-Associated Virus Integration and Replication during Coinfection with Herpes Simplex Virus 1.Generation and characterization of chimeric recombinant AAV vectors.Nephron segment-specific gene expression using AAV vectors.
P2860
Q24608049-629AB84E-0D9C-468C-A3FF-AD446BD56C4BQ24634560-17C2497E-C5BE-41F4-8263-E46C685B8CC3Q24634801-E6ED9838-CCA2-4C52-A2DC-276F5E7410BDQ27681034-F20E62D0-3154-4BCE-8FC4-5D9391C8A802Q28080450-924F6160-1592-45FB-9B8F-4ABE422E6843Q30413287-3959DDD8-905E-4874-85B9-337A27DDFA93Q30414524-0BE8B9C3-1620-48B4-B06D-6360484C31B8Q30417445-97608132-D470-4083-A04A-39B84419F0F5Q30419813-8A0FEC3E-5361-4006-AB70-F1979F5BFBF2Q33186207-B4B5F425-0A32-421A-9996-C0634EF22D9AQ33713348-6EBFEE83-6DAD-4973-AB75-A8CC98B3B513Q33763673-5D9BFFA4-96E5-4783-86FF-42793A4EA271Q34069571-FA7DC81F-2985-45FD-8D1F-01305960B6EFQ34142848-8CF68A67-5472-49D7-9A3E-2BB238C853FEQ34193457-A90BB3B7-3AB0-4610-8BBE-9C646169EFE0Q34994506-30239363-F937-4414-B241-D27B8701E7B0Q35000819-F067823D-666C-47FE-8496-CD94114A44ACQ35022838-DCF54612-670E-4A87-B206-4D14B259CA3CQ35043830-E22E613C-67F5-44C5-9728-01BBBFEC6FF4Q35306158-015460E0-A9A0-41FB-85CC-07E2BCB0AA16Q35543174-BEB5F32A-730A-47F7-B89E-03A5A5BE36FDQ35960506-9D81612D-0DC0-4E6C-9145-B9320CF5A8ABQ36348346-334FD6C2-8E87-4981-AA60-58C9CA02F92AQ36484108-678CEE91-D3CF-469B-8D73-46770B78DC47Q37015424-14EDD807-3E3E-4CE9-9700-68E66A3477DDQ37041512-BBC4E5A7-D495-49F3-85F0-6DF17B6B0057Q37051580-A7ABB24C-9EBB-4349-AC01-7BD81542CA31Q37364038-EEDC611F-49A2-4E67-B0DD-E5CE3F3CD205Q37721711-A4342F78-DCD3-41C8-9373-63CBBA406E8FQ39644453-0185BA6D-0E32-4970-A978-388827FADF2FQ40091715-36E61F55-6D06-4372-A4CB-7AE3B13B3AE4Q40161739-F66A9D0E-7426-4B4B-92F1-03264F86E525Q40334450-49663B68-B024-4B28-B276-9A89662A8B12Q40419511-81FAE5FF-B68E-47BB-A440-7979A1CC3132Q40471736-BFD54C2F-96D3-4BA7-84B8-91812080F8ABQ40804917-0B215AF5-AFE6-4BB4-A62D-8E3F162BB8BDQ40814049-57128800-D0C5-4D00-AA2E-B4BD19E2EE03Q41295569-E29C55D8-11A1-4E1A-8958-938D66D38C64Q41869331-8F126FB1-B8A8-44C4-A670-53691AB55F8FQ50178823-9B6126EE-168D-45CF-BC9E-FA86C81C783C
P2860
Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Latent adeno-associated virus ...... es in a nonhuman primate model
@ast
Latent adeno-associated virus ...... es in a nonhuman primate model
@en
Latent adeno-associated virus ...... es in a nonhuman primate model
@en-gb
Latent adeno-associated virus ...... es in a nonhuman primate model
@nl
type
label
Latent adeno-associated virus ...... es in a nonhuman primate model
@ast
Latent adeno-associated virus ...... es in a nonhuman primate model
@en
Latent adeno-associated virus ...... es in a nonhuman primate model
@en-gb
Latent adeno-associated virus ...... es in a nonhuman primate model
@nl
prefLabel
Latent adeno-associated virus ...... es in a nonhuman primate model
@ast
Latent adeno-associated virus ...... es in a nonhuman primate model
@en
Latent adeno-associated virus ...... es in a nonhuman primate model
@en-gb
Latent adeno-associated virus ...... es in a nonhuman primate model
@nl
P2093
P2860
P3181
P1433
P1476
Latent adeno-associated virus ...... es in a nonhuman primate model
@en
P2093
P2860
P304
P3181
P407
P577
1999-10-01T00:00:00Z